{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:21:11Z","timestamp":1768530071829,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170663"],"award-info":[{"award-number":["32170663"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470681"],"award-info":[{"award-number":["32470681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["875510"],"award-info":[{"award-number":["875510"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115766"],"award-info":[{"award-number":["115766"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011889","name":"Diamond Light Source","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011889","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004270","name":"Kungliga Tekniska H\u00f6gskolan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.trsl.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:44:06Z","timestamp":1757519046000},"page":"36-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combining computational target prioritization and a B cell maturation assay for target evaluation studies in systemic lupus erythematosus"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4480-6095","authenticated-orcid":false,"given":"Ming-Mei","family":"Shang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M\u00f6ller","family":"Westerberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeepta Kumar","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning Xu","family":"Land\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian C.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-2837","authenticated-orcid":false,"given":"Louise","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2025.09.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.trsl.2025.09.002_bib0002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"key":"10.1016\/j.trsl.2025.09.002_bib0003","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41927-023-00358-3","article-title":"Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)","volume":"7","author":"Chan","year":"2023","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000239","article-title":"Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments","volume":"4","author":"Touma","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.trsl.2025.09.002_bib0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1016\/j.trsl.2025.09.002_bib0006","first-page":"2658","volume":"9","author":"Vukelic","year":"2018","journal-title":"Novel Treatments in Lupus. Front Immunol."},{"key":"10.1016\/j.trsl.2025.09.002_bib0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nbt0119-7","article-title":"Lupus in crisis: as failures pile up, clinicians call for new tools","volume":"37","author":"Dolgin","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0008","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0961203320982668","article-title":"Rituximab - the first twenty years","volume":"30","author":"Leandro","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2025.09.002_bib0009","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2025.09.002_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2025.09.002_bib0011","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nrrheum.2016.191","article-title":"Systemic lupus erythematosus: extent and patterns of off-label use of rituximab for SLE","volume":"12","author":"Sanz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2025.09.002_bib0013","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.22993","article-title":"Pragmatic treatment of patients with systemic Lupus Erythematosus with Rituximab: long-term effects on serum immunoglobulins","volume":"69","author":"Reddy","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.trsl.2025.09.002_bib0014","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2025.09.002_bib0015","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2025.09.002_bib0016","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaut.2016.06.020","article-title":"The critical role of epigenetics in systemic lupus erythematosus and autoimmunity","volume":"74","author":"Long","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.trsl.2025.09.002_bib0017","first-page":"913","article-title":"A family survey of lupus erythematosus. 1. Heritability","volume":"14","author":"Lawrence","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0018","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ng.3603","article-title":"Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus","volume":"48","author":"Morris","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2025.09.002_bib0019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ng.3496","article-title":"High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry","volume":"48","author":"Sun","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2025.09.002_bib0020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-023-36306-5","article-title":"Multi-ancestry and multi-trait genome-wide association meta-analyses inform clinical risk prediction for systemic lupus erythematosus","volume":"14","author":"Khunsriraksakul","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2025.09.002_bib0021","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2025.09.002_bib0022","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41588-019-0456-1","article-title":"A genetics-led approach defines the drug target landscape of 30 immune-related traits","volume":"51","author":"Fang","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2025.09.002_bib0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trsl.2020.09.003","article-title":"Identifying novel B-cell targets for chronic inflammatory autoimmune disease by screening of chemical probes in a patient-derived cell assay","volume":"229","author":"Sundstr\u00f6m","year":"2020","journal-title":"Translational Research"},{"key":"10.1016\/j.trsl.2025.09.002_bib0024","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1471-2105-10-168","article-title":"Fpocket: an open source platform for ligand pocket detection","volume":"10","author":"Le Guilloux","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.trsl.2025.09.002_bib0025","doi-asserted-by":"crossref","first-page":"D685","DOI":"10.1093\/nar\/gkq1039","article-title":"Pathway Commons, a web resource for biological pathway data","volume":"39","author":"Cerami","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.trsl.2025.09.002_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.trsl.2025.09.002_bib0027","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.trsl.2025.09.002_bib0028","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.trsl.2025.09.002_bib0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.trsl.2025.09.002_bib0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.trsl.2025.09.002_bib0031","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0032","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2025.09.002_bib0033","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"10.1016\/j.trsl.2025.09.002_bib0034","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jbiotec.2005.06.014","article-title":"Choice of the adequate detection time for the accurate evaluation of the efficiency of siRNA-induced gene silencing","volume":"120","author":"Choi","year":"2005","journal-title":"J Biotechnol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/nat.2013.0466","article-title":"Target gene abundance contributes to the efficiency of siRNA-mediated gene silencing","volume":"24","author":"Hong","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.trsl.2025.09.002_bib0036","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2025.09.002_bib0037","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jim.2010.06.009","article-title":"Abnormalities of B cell subsets in patients with systemic lupus erythematosus","volume":"363","author":"Dorner","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.trsl.2025.09.002_bib0038","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0039","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: A meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0040","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2025.09.002_bib0041","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0961203316643172","article-title":"B-cell subsets, signaling and their roles in secretion of autoantibodies","volume":"25","author":"Iwata","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.trsl.2025.09.002_bib0042","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2018.03.009","article-title":"Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins","volume":"457","author":"Wu","year":"2018","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.trsl.2025.09.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2003213","article-title":"Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the connectivity Map","volume":"15","author":"Smith","year":"2017","journal-title":"PLoS Biol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0044","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3389\/fimmu.2019.01652","article-title":"RNAi transfection optimized in primary naive B cells for the targeted analysis of Human plasma cell differentiation","volume":"10","author":"Shih","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/mp060026i","article-title":"Kinetic and efficacy analysis of RNA interference in stably and transiently expressing cell lines","volume":"3","author":"Amy","year":"2006","journal-title":"Molecular Pharmaceuticals"},{"key":"10.1016\/j.trsl.2025.09.002_bib0046","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3389\/fimmu.2017.01938","article-title":"B cell-intrinsic role for IRF5 in TLR9\/BCR-induced Human B cell activation, proliferation, and plasmablast differentiation","volume":"8","author":"De","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.trsl.2025.09.002_bib0047","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.trsl.2025.09.002_bib0048","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of efficacy and safety of Ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2025.09.002_bib0049","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2025.09.002_bib0050","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2025.09.002_bib0051","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2025.09.002_bib0052","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/imt.14.83","article-title":"Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases","volume":"6","author":"Ballesteros-Tato","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.trsl.2025.09.002_bib0053","doi-asserted-by":"crossref","first-page":"e1293","DOI":"10.1002\/cti2.1293","article-title":"Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the tfr\/tfh ratio in lupus","volume":"10","author":"Liang","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.trsl.2025.09.002_bib0054","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2025.09.002_bib0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-015-0551-3","article-title":"Long-lived plasma cells are early and constantly generated in New Zealand Black\/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors","volume":"17","author":"Taddeo","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.trsl.2025.09.002_bib0056","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89569","article-title":"Kruppel-like factor4 regulates PRDM1 expression through binding to an autoimmune risk allele","volume":"2","author":"Jang","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2025.09.002_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.trsl.2025.09.002_bib0058","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41586-020-2277-x","article-title":"Complement genes contribute sex-biased vulnerability in diverse disorders","volume":"582","author":"Kamitaki","year":"2020","journal-title":"Nature"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524425000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524425000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:17:28Z","timestamp":1768472248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524425000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":58,"alternative-id":["S1931524425000908"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2025.09.002","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining computational target prioritization and a B cell maturation assay for target evaluation studies in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}